Literature DB >> 29278015

An overview on the current status of cancer nanomedicines.

Nasimudeen R Jabir1, Khalid Anwar2, Chelapram K Firoz1, Mohammad Oves3, Mohammad Amjad Kamal1, Shams Tabrez1.   

Abstract

PURPOSE: Cancer remains a significant cause of morbidity and mortality across the globe. A recent report suggests around 14.1 million new cases and 8.2 million cancer-related deaths, which are expected to reach 21.7 million and 13 million by 2030 worldwide, respectively.
MATERIALS AND METHODS: Because of highly complex mechanisms of cancer progression, it is important to explore and develop new innovative technologies which are more efficient compared with presently available treatment options.
RESULTS: Currently, chemotherapy, radiation and surgery are the most commonly used cancer treatment methods. In the last decade, nanomedicine emerged as an alternative treatment option that uses specific drug-delivery systems, improves efficacy of drugs and reduces detrimental side effects to normal tissues.
CONCLUSION: In this review, we have summarized cancer nanomedicines (active and passive drug delivery) available in the market. We have also discussed other nanomedicines that are at different stages of clinical trials.

Entities:  

Keywords:  Cancer; drug delivery; nanomedicines; nanotechnology; site specific

Mesh:

Substances:

Year:  2018        PMID: 29278015     DOI: 10.1080/03007995.2017.1421528

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest.

Authors:  Saif A Alharthy; Shams Tabrez; Ahmed A Mirza; Torki A Zughaibi; Chelapram K Firoz; Mycal Dutta
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-29       Impact factor: 2.650

2.  Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles.

Authors:  Baozhen Zhang; Mingbin Zheng; Lintao Cai; Xiujun Fan
Journal:  J Vis Exp       Date:  2018-09-18       Impact factor: 1.355

3.  Polyamidoamine Dendrimers Decorated Multifunctional Polydopamine Nanoparticles for Targeted Chemo- and Photothermal Therapy of Liver Cancer Model.

Authors:  Bartosz F Grześkowiak; Damian Maziukiewicz; Agata Kozłowska; Ahmet Kertmen; Emerson Coy; Radosław Mrówczyński
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

4.  Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).

Authors:  Nazli Sotoudeh; Zahra Noormohammadi; Mahdi Habibi-Anbouhi; Fatemeh Kazemi-Lomedasht; Mahdi Behdani
Journal:  Iran J Basic Med Sci       Date:  2021-09       Impact factor: 2.699

Review 5.  Fullerenes for the treatment of cancer: an emerging tool.

Authors:  Neha Benedicta Fernandes; Raghavendra Udaya Kumar Shenoy; Mandira Kashi Kajampady; Cleona E M DCruz; Rupesh K Shirodkar; Lalit Kumar; Ruchi Verma
Journal:  Environ Sci Pollut Res Int       Date:  2022-07-06       Impact factor: 5.190

6.  Antiproliferative activity, cell-cycle arrest, apoptotic induction and LC-HRMS/MS analyses of extracts from two Linum species.

Authors:  Ryma Mouna; Alexis Broisat; Abdalwahab Ahmed; Marlène Debiossat; Ahcène Boumendjel; Catherine Ghezzi; Zahia Kabouche
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 7.  Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review.

Authors:  Afrasim Moin; Syed Mohd Danish Rizvi; Talib Hussain; D V Gowda; Gehad M Subaiea; Mustafa M A Elsayed; Mukhtar Ansari; Abulrahman Sattam Alanazi; Hemant Yadav
Journal:  Life (Basel)       Date:  2021-05-05

Review 8.  Functions of polyphenols and its anticancer properties in biomedical research: a narrative review.

Authors:  Pritam Bhagwan Bhosale; Sang Eun Ha; Preethi Vetrivel; Hun Hwan Kim; Seong Min Kim; Gon Sup Kim
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.